Compare e l f Beauty Inc (ELF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs State Street SPDR S&P Biotech ETF — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ELF | XBI | |
|---|---|---|
Market Cap | $6.20B | $10.08B |
Volume | 1,301,240 | 9,534,635 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $144.97 | $169.55 |
52-Week Low | $49.57 | $104.99 |
Typical Hold Time | 25 Days | 37 Days |
Enterprise Value | $6.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
